BridgeMD
Tests treatment safety and results for Parkinson Disease
Official title The Efficacy and Safety of Precision REpetitive Transcranial Magnetic Stimulation in Alleviating Motor Symptom in Parkinson's Disease
ClinicalTrials.gov ID: NCT06383247
What this study is testing
- What it's testing
- Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older
You may be able to join if
- Age ≥ 40 years old;
- Meet the diagnostic criteria for idiopathic Parkinson's disease (MDS Diagnostic Criteria for Parkinson's Disease (2015 Edition))[1];
- Have no history of drug adjustment within 4 weeks before treatment and the entire study period;
- The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4;
- MMSE ≥22，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.
You likely can't join if
- Previously head MRI/CT was focal brain injury or severe leukoencephalopathy (Fazekas grade 3 and above);
- Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);
- Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;
- There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.
- The person has a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures;
- Diagnosed with a neuropsychiatric disorder other than PD
See the full eligibility criteria
- Age ≥ 40 years old;
- Meet the diagnostic criteria for idiopathic Parkinson's disease (MDS Diagnostic Criteria for Parkinson's Disease (2015 Edition))[1];
- Have no history of drug adjustment within 4 weeks before treatment and the entire study period;
- The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4;
- MMSE ≥22，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.
- Previously head MRI/CT was focal brain injury or severe leukoencephalopathy (Fazekas grade 3 and above);
- Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);
- Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;
- There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.
- The person has a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures;
- Diagnosed with a neuropsychiatric disorder other than PD
- Have a history of drug abuse or drug use;
- Participants in any clinical trial within the previous 6 month;
- Pregnant/lactating women or people (including men) who have a birth plan within 6 months;
- Other conditions deemed unsuitable for inclusion by the investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Hefei, Anhui, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hefei, Anhui, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.